87 related articles for article (PubMed ID: 19419885)
21. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
22. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer: Vancouver Island Cancer Centre experience.
Ludgate CM; Lim JT; Wilson AG; Alexander AS; Wilson KS
Can J Urol; 2000 Feb; 7(1):937-43. PubMed ID: 11121249
[TBL] [Abstract][Full Text] [Related]
24. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?
Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
Radiat Oncol Investig; 1999; 7(4):249-59. PubMed ID: 10492166
[TBL] [Abstract][Full Text] [Related]
26. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
Macdonald OK; Schild SE; Vora SA; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
J Urol; 2003 Nov; 170(5):1833-7. PubMed ID: 14532786
[TBL] [Abstract][Full Text] [Related]
28. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
29. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
30. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
31. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
[TBL] [Abstract][Full Text] [Related]
33. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer: a retrospective analysis.
Fiorica F; Berretta M; Colosimo C; Berretta S; Ristagno M; Palmucci T; Palmucci S; Lleshi A; Ursino S; Fisichella R; Spartà D; Stefanelli A; Cappellani A; Tirelli U; Cartei F
Arch Gerontol Geriatr; 2010; 51(3):277-82. PubMed ID: 20044153
[TBL] [Abstract][Full Text] [Related]
35. Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome.
Kubes J; Dedeckova K; Cvek J; Vondrácek V; Dvorak J; Argalacsová S; Navrátil M; Buril J
J BUON; 2013; 18(3):669-74. PubMed ID: 24065481
[TBL] [Abstract][Full Text] [Related]
36. [Survival among patients with prostate cancer after distant radiotherapy and low-intensity near-infrared phototherapy].
Zharinov GM; Zimin AA; Samoĭlova KA; Neklasova NIu
Vopr Onkol; 2011; 57(4):457-61. PubMed ID: 22191234
[TBL] [Abstract][Full Text] [Related]
37. Carbon ion radiotherapy for treatment of prostate cancer and subsequent outcomes after biochemical failure.
Shimazaki J; Tsuji H; Ishikawa H; Okada T; Akakura K; Suzuki H; Harada M; Tsujii H
Anticancer Res; 2010 Dec; 30(12):5105-11. PubMed ID: 21187497
[TBL] [Abstract][Full Text] [Related]
38. Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer.
Gogna NK; Baxi S; Hickey B; Baumann K; Burmeister E; Holt T
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e205-11. PubMed ID: 22342096
[TBL] [Abstract][Full Text] [Related]
39. [The role and principles of radiotherapy in prostate cancer in the elderly subject].
Richaud P; Salomon L; Mongiat-Artus P; Gaschignard N; Beuzeboc P; Peyromaure M; Bastide C; Cornud F; Molinié V; Rozet F; Staerman F; Soulié M
Prog Urol; 2009 Nov; 19 Suppl 3():S156-9. PubMed ID: 20123502
[TBL] [Abstract][Full Text] [Related]
40. [Urological cancers of the elderly subject: the role of radiotherapy].
Hennequin C; Quéro L
Prog Urol; 2009 Nov; 19 Suppl 3():S96-9. PubMed ID: 20123510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
